Admin Login
My Saved Results
Newsletter
Contact

TRIALS & PROVIDERS

Find An NCORP Trial

NCORP Trials

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Status

Completed

Cancer Type

Hodgkin Lymphoma

Trial Phase

Phase II

Eligibility

18 Years and older, Male and Female

Study Type

Treatment

NCD ID

NCT01716806

Protocol IDs

SGN35-015 (primary)

Study Sponsor

Seagen Inc.

NCI Full Details

http://clinicaltrials.gov/show/NCT01716806

Summary

This trial will study brentuximab vedotin to find out whether it is an effective treatment
for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study
will be older or will have other conditions that make them unable to have standard
chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with
other drugs.

Objectives

This study is designed to evaluate the efficacy and tolerability of brentuximab vedotin as
monotherapy and in combination with other agents as frontline therapy. There are 6 parts of
the study. The population to be studied includes treatment-naïve patients with classical
Hodgkin lymphoma (HL) or treatment-naïve patients with CD30-expressing peripheral T-cell
lymphoma (PTCL).

Treatment Sites

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
Northside Hospital Central Research Department
404-303-3355
www.northside.com

STAY INFORMED!

CALL EMAIL